Linc-KILH potentiates Notch1 signaling through inhibiting KRT19 phosphorylation and promotes the malignancy of hepatocellular carcinoma

Long noncoding RNAs (LncRNAs) are emerging as crucial regulators in the pathophysiological process of various tumors, including HCC. Here, we identify a novel lncRNA Linc-KILH (KRT19 interacting long noncoding RNA in hepatocellular carcinoma), which is significantly up-regulated in HCC tissues and positively correlated with larger tumor size, severer microvascular invasion, more intrahepatic metastasis and decreased survival of HCC patients. Silence of Linc-KILH remarkably inhibited the proliferation and metastasis abilities of KRT19-positive HCC cells in vitro and in vivo. Mechanistically, Linc-KILH interacts with KRT19 and then inhibits the phosphorylation of KRT19 on Ser35, thereby, enhancing the translocation of KRT19 from cytoplasm to membrane in KRT19 positive HCC cells. Additionally, we validated that KRT19 interacts with beta-catenin but not RAC1 in HCC cells. Linc-KILH enhanced the interaction between beta-catenin and KRT19 in cytoplasm and promoted the nuclear translocation of beta-catenin in HCC cells. Furthermore, Linc-KILH could enhance the promoting function of KRT19 on Notch1 signaling with the existence of KRT19 in HCC cells. Collectively, we revealed that Linc-KILH exerts a vital function in KRT19 positive HCC progression and may likely be developed into an effective therapeutic target for HCC.

Automated summary

Recent research has identified a novel lncRNA Linc-KILH, which is significantly up-regulated in HCC tissues and positively correlated with tumor size, microvascular invasion, intrahepatic metastasis and decreased survival in HCC patients. Silencing Linc-KILH can inhibit the proliferation and metastasis abilities of KRT19-positive HCC cells. Mechanistically, Linc-KILH interacts with KRT19 and inhibits the phosphorylation of KRT19, leading to enhanced translocation of KRT19 in HCC cells.